DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20175594

A 6-month-old male infant refuses to move his left leg

Evie Huang, Unikora Yang, Mona P. Gera

Abstract


Chronic granulomatous disease (CGD) is a rare, genetically heterogeneous condition that occur from mutations in NADPH oxidase, resulting in recurrent infections from catalase-positive organisms and granuloma formation. It is most commonly diagnosed within the first two years of life. We present a case of a six-month-old infant who presented with left tibial pain with initial concerns for child abuse and was found to have CGD. A skeletal survey revealed multiple lytic lesions, diffuse osteopenia, and opacities in the lungs. MRI revealed a tibial subperiosteal abscess and, after incision and drainage, cultures grew Serratia marcescens, an unusual catalase-positive organism. Targeted testing for immunodeficiency revealed 0% NADPH oxidase activity on nitro blue tetrazolium (NBT), confirming the diagnosis. 


Keywords


Chronic granulomatous disease, Catalase-positive organisms, DHR test, NADPH oxidase, NBT test

Full Text:

PDF

References


Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1):89-99.

Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Med (Baltimore). 2000;79(3):170-200.

Kang EM, Marciano BE, DeRavin S, Zarember K, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplant. J Allergy Clin Immunol. 2011;127(6):1319-26.

Bonilla FA, Geha RS. Primary immunodeficiency disease. J Allergy Clin Immunol. 2003;111(2):S571-81.

Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, Vandivier RW, Harry BL, et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood. 2009;113(9):2047-55.

Jones LBKR, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, et al. Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152(2):211-8.

Gatlin JI, Malech HL, Weening RS, Curnutte JT, Quie PG, Jaffe HS, et al. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324(8):509-16.

van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234.

Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140(3):255-66.

Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600-10.

Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176-83.

Leiding JW, Holland SM. Chronic granulomatous disease. Gene Reviews®: 2012. Available at https://www.ncbi.nlm.nih.gov/books/NBK99496/ Accessed 28 August 2017.